Evidence map›Paper›PMID 35690723›Full record

GuidelineThe journal of headache and pain2022

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.

Simona Sacco, Faisal Mohammad Amin, Messoud Ashina, Lars Bendtsen, Christina I Deligianni, Raquel Gil-Gouveia, Zaza Katsarava, Antoinette MaassenVanDenBrink, Paolo Martelletti, Dimos-Dimitrios Mitsikostas and 8 more

2 registry-linked trialsOpen access · goldAbstract readSystematic ReviewPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in The journal of headache and pain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 194 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed, 17 pooled it
60.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05442008 completednot on this map

Study of Early MIDAS Reduction at 3 Months as Predictor of Long-term Erenumab Treatment in Chronic Migraine: a Real-life, Open-label, Trial

TypeobservationalSponsorIRCCS National Neurological Institute "C. Mondino" FoundationRan2018 to 2021Enrolled53ConditionsMigraineArmsErenumab 70/140 mg s.c.
NCT07040813 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

A Randomized Placebo-controlled Double-blind Phase III Trial to Investigate the Reduction of Monthly Migraine Days (MMDs) Over 12 Weeks of Treatment With CGRP mAbs and Onabotulinumtoxin A Intramuscularly Compared With CGRP mAbs and Placebo in Chronic Migraine

TypeinterventionalSponsorOslo University HospitalRan2025 to 2029Enrolled450ConditionsMigraine, Chronic Migraine HeadacheArmsCGRP mAbs and onabotulinumtoxin A, CGRP mAbs and placebo
3 · Its place in the literature

Who cites it

194 citing papers in PubMed, 17 syntheses or guidelines pooled it, 427 citations in OpenAlex.

  1. Efficacy and safety of CGRP monoclonal antibodies in chronic migraine: a systematic review integrating randomized and real-world evidence.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Migraine management in Saudi Arabia: An expert consensus.Neurosciences (Riyadh, Saudi Arabia) · 2025
    Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Guideline
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Trial

134 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 15 institutions in 10 countries.

Simona SaccoDepartment of Biotechnological and Applied Clinical Sciences - University of L'Aquila, Via Vetoio 1, L'Aquila, Italy. simona.sacco@univaq.it.
Faisal Mohammad AminDanish Headache Center, Department of Neurology, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark.
Messoud AshinaDanish Headache Center, Department of Neurology, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark.
Lars BendtsenDanish Headache Center, Department of Neurology, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark.
Christina I DeligianniDanish Headache Center, Department of Neurology, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark.
Raquel Gil-GouveiaHospital da Luz Headache Center, Neurology Department, Hospital da Luz Lisboa, Lisbon, Portugal.
Zaza KatsaravaChristian Hospital Unna, Unna, Germany.
Antoinette MaassenVanDenBrinkDepartment of Internal Medicine, Erasmus MC Medical Center, Rotterdam, The Netherlands.
Paolo MartellettiDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Dimos-Dimitrios Mitsikostas1st Department of Neurology, Aeginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Raffaele OrnelloDepartment of Biotechnological and Applied Clinical Sciences - University of L'Aquila, Via Vetoio 1, L'Aquila, Italy.
Uwe ReuterDepartment of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Margarita Sanchez-Del-RioDepartment of Neurology, Clinica Universidad de Navarra, Madrid, Spain.
Alexandra J SinclairInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Gisela TerwindtDepartment of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
Derya UluduzDepartment of Neurology Istanbul Cerrahpasa Medical Faculty, Istanbul, Turkey.
Jan VersijptDepartment of Neurology, Vrije Universiteit Brussel (VUB), Universitair, Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Christian LamplDepartment of Neurology, Headache Medical Center at the Konventhospital BHB Linz, Linz, Austria.
University of Copenhagen · DKUniversity of L'Aquila · ITClinica Universidad de Navarra · ESConvent Hospital of the Brothers of Saint John of God · ATErasmus MC · NLGlostrup Hospital · DKLeiden University Medical Center · NLNational and Kapodistrian University of Athens · GRRigshospitalet · DKSapienza University of Rome · ITUniversidade Católica Portuguesa · PTUniversitair Ziekenhuis Brussel · BEUniversitätsmedizin Greifswald · DEUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized controlled trials (RCTs) and real-world evidence have expanded the evidence and knowledge for those treatments. Therefore, the EHF panel decided to provide an updated guideline on the use of those treatments.

methodsThe guideline was developed following the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The working group identified relevant questions, performed a systematic review and an analysis of the literature, assessed the quality of the available evidence, and wrote recommendations. Where the GRADE approach was not applicable, expert opinion was provided.

resultsWe found moderate to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and galcanezumab in individuals with episodic and chronic migraine. For several important clinical questions, we found not enough evidence to provide evidence-based recommendations and guidance relied on experts' opinion. Nevertheless, we provided updated suggestions regarding the long-term management of those treatments and their place with respect to the other migraine preventatives.

conclusionMonoclonal antibodies targeting the CGRP pathway are recommended for migraine prevention as they are effective and safe also in the long-term.

Indexed as

Calcitonin Gene-Related PeptideMigraine DisordersAntibodies, MonoclonalCalcitonin Gene-Related Peptide Receptor AntagonistsHeadacheHumansAntibodies, MonoclonalCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsCalcitonin gene-related pathwayGuidelineMigraineMonoclonal antibodiesPrevention

Identifiers

PMID35690723
PMCPMC9188162
OpenAlexW4282934967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.